Glioblastoma Pipeline Analysis: Major Pharmaceutical Players Ready to Develop New Therapies and Explore Countless Opportunities

0

by DelveInsight Glioblastoma 2022 Pipeline Overview provides comprehensive global coverage of glioblastoma therapies available, marketed and in development at various stages of clinical development, major pharmaceutical companies are striving to advance the pipeline space and future growth potential of the glioblastoma pipeline field. glioblastoma.

For emerging glioblastoma drugs, the glioblastoma pipeline analysis report provides a 360° view of the therapeutic landscape by development point, product type, route of administration, molecule type, and mode of action. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Some of the Highlights from the Glioblastoma Pipeline Report

  • More 100+ Glioblastoma pipeline therapies are at various stages of growth, and their anticipated acceptance in the Glioblastoma market would significantly increase market revenue.
  • Major glioblastoma companies such as Array Biopharma, AstraZeneca, Doule bond Pharmaceuticals, Philogen, Immatics NV, BioNTech, InovioPharma, Noxxon Pharma, Celgene Corporation, Karyo Pharma, Neugate Theranostics, Novartis, Orphelia Pharma, Merck, Acerta Pharma, Genenta Science, CNS Pharmaceutical, Pfizer, Roche, Oncotelic Therapeutics, Autotelic Therapeutics, ACADIA Pharmaceuticals, Mayo Clinic, Cytogel, Xgene Pharmaceutical, Ascletis, 3-V Biosciences, Yumanity Therapeutics, and others are evaluating new drug candidates for the treatment of glioblastoma to improve the treatment landscape.
  • Major therapies in the glioblastoma pipeline at various stages of development include Onfekafuspalfa, PLX3397, APVAC1, INO5401, Pegol olaptes, Selinexor, L19TNF, H1PV, NG101m, ACP196, Temferon, Berubicin hydrochloride, VXM01, Avelumab, Trabedersen, TVB2640, AZD1390, YTX7739, WP1122, and others.
  • Among the emerging therapies for glioblastoma, Trabedersen is in Phase III clinical development, whereas, Selinexor is in phase II trials.
  • Early-stage glioblastoma pipeline therapies include AZD1390 in Phase I clinical trials.

Request a sample and learn about recent advances in the treatment of glioblastoma @ Glioblastoma Pipeline Overview and Prospects

Overview of Glioblastoma

Glioblastoma is a deadly form of cancer that can develop in the brain or spinal cord. Glioblastoma develops from astrocytes, which are cells that feed nerve cells. It can develop at any age, but is more common in older people. It can aggravate headaches, nausea, vomiting, and seizures. The causes of glioblastoma are unknown.

Symptoms of glioblastoma vary depending on the type of tumor, as well as the size, location, and growth rate of the tumor. Symptoms of glioblastoma include headache, nausea or vomiting, confusion or deterioration in brain function, memory loss, personality changes or irritability and difficulty with balance. Computed tomography (CT or CAT scan) and magnetic resonance imaging (MRI) are two diagnostic instruments (MRI) widely used for the diagnosis of glioblastoma. Glioblastoma treatments can slow cancer progression and reduce signs and symptoms.

For more information on the disease, causes and treatment, visit: Glioblastoma Pipeline Landscape

Glioblastoma Pipeline Analysis: Pharmaceutical Profile

TVB2640:Ascletis Pharma

TVB2640 is an oral selective fatty acid synthase (FASN) inhibitor. By inhibiting novo lipogenesis, TVB2640 reduces energy intake and disrupts the composition of membrane phospholipids in tumor cells (DNL). FASN is a critical enzyme that regulates DNL. It is currently in phase III development for the treatment of glioblastoma.

Trabedersen: Oncotelic therapy

Trabedersen is an antisense inhibitor of TGF-2 used to treat solid tumors, particularly brain cancer in adults and DIPG in children. Trabedersen (OT101) is a novel antisense oligodeoxynucleotide (ODN) developed by Oncotelic for the treatment of patients with pancreatic carcinoma, malignant melanoma, colorectal carcinoma, high-grade glioma (HGG) and other cancers that overexpress TGF-2 (e.g. carcinoma of prostate, renal cell carcinoma, etc.). TGF- is overexpressed in malignant tumors, suppressing the host’s innate immune response to tumors. OT-101 treatment suppresses the camouflaging effect of TGF, allowing innate or therapeutic immunity to target and eradicate tumors. Currently, the drug is in phase III development for the treatment of glioblastoma.

Gaining more knowledge about emerging drugs for glioblastoma @ Glioblastoma treatment drugs

Glioblastoma pipeline therapies and key companies

  • TVB2640:Ascletis Pharma
  • Trabedersen: Oncotelic therapy
  • Selinexor: Karyopharm Therapeutics
  • Onfekafuspalfa: Philogene
  • AZD1390: AstraZeneca
  • YTX7739: Yumanity Therapeutics

Learn more about FDA-approved drugs for glioblastoma @ Glioblastoma Clinical Trials

  1. Monotherapy
  2. Combination therapy
  1. Discovery
  2. Preclinical
  3. Phase I
  4. Phase II
  5. Phase III
  6. Pre-registration
  • By administration
  1. Oral
  2. Parenteral
  3. intravitreal
  4. subretinal
  5. Topical
  1. Monoclonal antibody
  2. peptides
  3. Polymer
  4. Small Molecule
  5. Genetical therapy

Scope of the Glioblastoma Report

Cover: Global

Key Glioblastoma Companies: Array Biopharma (NYSE: ARRY), AstraZeneca (NASDAQ: AZN), Doule Bond Pharmaceuticals, Philogen (BIT: PHIL), Immatics NV (NASDAQ: IMTX), BioNTech (NASDAQ: BNTX), InovioPharma, Noxxon Pharma (EPA: ALNOX) , Celgene Corporation, Karyo Pharma (NASDAQ: KPTI), Neugate Theranostics, Novartis (NYSE: NVS), Orphelia Pharma, Merck (NYSE: MRK), Acerta Pharma, Genenta Science (NASDAQ: GNTA), CNS Pharmaceutical (NASDAQ: CNSP) , Pfizer (NYSE: PFE), Roche (SWX: ROG), Oncotelic Therapeutics (OTCMKTS: OTLC), Autotelic Therapeutics, ACADIA Pharmaceuticals (NASDAQ: ACAD), Mayo Clinic, Cytogel, Xgene Pharmaceutical, Ascletis (OTCMKTS: ASCLF), 3 -V Biosciences, Yumanity Therapeutics (NASDAQ: YMTX) and others

Key Therapies in the Glioblastoma Pipeline: Onfekafuspalfa, PLX3397, APVAC1, INO5401, Pegol olaptes, Selinexor, L19TNF, H1PV, NG101m, ACP196, Temferon, Berubicin hydrochloride, VXM01, Avelumab, Trabedersen, TVB2640, AZD1390, YTX7739, WP1122and others

Contents

1. Glioblastoma Pipeline Report Overview
2. Executive Summary of Glioblastoma Pipeline Report
3. Glioblastoma pipeline: overview
4. Analytical perspective In-depth business assessment
5. Glioblastoma pipeline therapeutics
6. Glioblastoma pipeline: late-stage products (pre-registration)
seven. Glioblastoma Pipeline: Late Stage Products (Phase III)
8. Glioblastoma pipeline: mid-stage products (Phase II)
9. Glioblastoma Pipeline: Early Stage Products (Phase I)
ten. Therapeutic Evaluation of the Glioblastoma Pipeline
11. Inactive Products in the Glioblastoma Pipeline
12. Analysis of company-university collaborations (license/partnership)
13. Key companies
14. Key Glioblastoma Pipeline Products
15. Unmet needs
16. Market Drivers and Barriers
17. Future prospects and conclusion
18. Analyst Views
19. Annex

You have questions ? Contact us for more information @ Glioblastoma Drug Pipeline Assessment

Related Reports

Glioblastoma market

Glioblastoma Market Overview, Epidemiology and Market Forecast-2032 The report provides an in-depth understanding of the disease, historical and forecasted epidemiology, as well as market trends, market drivers, market barriers and major glioblastoma companies, including Orphelia Pharma, Merck, Acerta Pharma, Genenta Science, CNS Pharmaceutical, Pfizer, Roche, among others.

Epidemiological predictions of glioblastoma

Epidemiological forecasts of glioblastoma until 2032 report provides an in-depth understanding of the disease, historical and projected epidemiology of glioblastoma in the 7MM i.e. USA, EU5 (Germany, Spain, Italy, France and UK) and Japan.

Recurring Glioblastoma Market

Recurrent Glioblastoma Market Overview, Epidemiology and Market Forecast-2032 The report provides an in-depth understanding of the disease, historical and forecast epidemiology, as well as market trends, market drivers, market barriers and Recurrent Glioblastoma key companies including Genenta Science, CNS Pharmaceutical, Pfizer, Roche, among others.

Glioblastoma Multiforme Market

Glioblastoma Multiforme Market Overview, Epidemiology and Market Forecast-2030 The report provides an in-depth understanding of the disease, historical and forecast epidemiology, as well as market trends, market drivers, market barriers and GBM major companies including CNS Pharmaceutical, Pfizer, Roche, Autotelic Therapeutics, among others.

Glioblastoma multiforme pipeline

Glioblastoma Multiforme Pipeline Overview, 2022 The report provides comprehensive information about the pipeline landscape, pipeline drug profiles including clinical and non-clinical stage products, and key glioblastoma multiforme societies, including CNS Pharmaceutical, Pfizer, Roche, Autotelic Therapeutics, among others.

Recurrent epidemiological predictions of glioblastoma

Epidemiological prediction of recurrent glioblastoma until 2032 The report provides an in-depth understanding of the disease, historical and projected recurrent epidemiology of glioblastoma in 7MM i.e. USA, EU5 (Germany, Spain, Italy, France and UK Kingdom) and Japan.

Other trend reports

Cell and Gene Therapy for Multiple Myeloma Market | fallopian tube cancer market | Atherectomy Devices Market | Oncolytic Virus Cancer Therapy Market | Urinary Incontinence Market | Cholangiocarcinoma Market | Tissue Heart Valves/Cardiovascular Prostheses Market | artificial discs market | obesity market | cerebral infarction market | Hematuria Market | Diabetes market | Spinal Fusion Devices Market | panuveitis market | Prosthetic Heart Valve Market

Latest Health Blogs

About DelveInsight

DelveInsight is a leading business consulting and market research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing complete end-to-end solutions to improve their performance.

Contact us

Sandeep Joshi

[email protected]

+1(919)321-6187

www.delveinsight.com

Share.

Comments are closed.